New role for Actos in MS

Industry has targeted peroxisome proliferation-activated receptors for metabolic indications since the 1990s. Now, a paper by German researchers suggests the PPAR agonist Actos pioglitazone could be useful for treating multiple sclerosis and other autoimmune diseases.1

The study assessed the effect of pioglitazone on experimental autoimmune encephalomyelitis (EAE), a widely used mouse model for MS. The drug appears to block the development of T helper type 17 (Th17) cells, which are implicated in autoimmunity.2

"There have been many publications about what determines the differentiation of Th17 cells," said Percy Knolle, professor of molecular medicine at the University of Bonn and senior author of The

Read the full 1010 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers